Chemotherapy can be more toxic to brain cells than to cancer cells and may cause brain damage

November 29, 2006

Drugs used to treat cancer may damage normal, healthy brain cells more than the cancer cells they are meant to target. A study published today in the open access journal Journal of Biology shows that clinical doses of chemotherapeutic drugs used to treat many common cancers cause long-term damage to the brains of mice by killing neural stem cells and oligodendrocytes, which produce the myelin insulation needed for normal neuronal function, and by impairing neural stem cell division. These results might explain the adverse neurological side effects - including reduction in cognitive abilities - observed in some cancer patients treated with chemotherapy. The approach used in the current study could also provide a rapid screening method to analyse new therapies and identify cell populations at risk during cancer treatment.

Joerg Dietrich and colleagues working in the group of Mark Noble, from the University of Rochester in the USA, exposed human neural stem cells, oligodendrocyte precursor cells and neuron-restricted precursor cells, in culture, to three chemotherapeutic agents: cisplatin, carmustine and cytarabine. Dietrich et al. also exposed different human cancer cell lines, such as uterine, breast or colon cancer cell lines to the same chemotherapeutic agents. Cisplatin is used to treat a wide range of cancers, including breast cancer, lung cancer and colon cancer and carmustine is used to treat brain tumours, Hodgkin and non-Hodgkin lymphomas. Both agents act by modifying the structure of DNA. Cytarabine, which interferes with cell metabolism, is used to treat leukaemia and lymphomas.

Dietrich et al.'s results show that clinical concentrations of cisplatin, carmustine and cytarabine are more toxic to human neural cells than to cancer cells. The drugs are toxic to both the dividing neural stem cells and the non-dividing cells such as astrocytes and neurons, even at very low concentrations. Results show that exposure to low micromolar concentrations of cisplatin, carmustine or cytarabine causes a 60-90% reduction in the viability of oligodendrocyte precursor cells and neuron precursor cells, but has little effect on most of the cancer cell lines examined. The authors show that to kill 40-80% of cancer cells, doses that also kill 70-100% of neural cells are required.

Using live mice treated with each of the drugs, Dietrich et al. show that cells of the nervous system of the mice continue to die for at least six weeks after the end of treatment. The drugs kill both dividing stem cells and non-dividing precursor cells of the nervous system in live mice. They also cause long-lasting reductions in cell division and proliferation in the central nervous system of the mice.
-end-
Article:
CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo
Joerg Dietrich, Ruolan Han, Yin Yang, Margot Mayer-Pröschel and Mark Noble
Journal of Biology 2006, 5:22 (30 November 2006)

BioMed Central

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.